Connection

Stefano Rusconi to Oxazines

This is a "connection" page, showing publications Stefano Rusconi has written about Oxazines.
Connection Strength

0.276
  1. Long-term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multi-centre cohort of HIV-1-infected, virologically suppressed patients. Int J Antimicrob Agents. 2019 Dec; 54(6):728-734.
    View in: PubMed
    Score: 0.043
  2. Durability of first-line regimens including integrase strand transfer inhibitors (INSTIs): data from a real-life setting. J Antimicrob Chemother. 2019 05 01; 74(5):1363-1367.
    View in: PubMed
    Score: 0.042
  3. Durability of dolutegravir plus boosted darunavir as salvage or simplification of salvage regimens in HIV-1 infected, highly treatment-experienced subjects. HIV Clin Trials. 2018 12; 19(6):242-248.
    View in: PubMed
    Score: 0.041
  4. Dolutegravir Plus Rilpivirine as a Switch Option in cART-Experienced Patients: 96-Week Data. Ann Pharmacother. 2018 08; 52(8):740-746.
    View in: PubMed
    Score: 0.039
  5. A dual regimen of ritonavir/darunavir plus dolutegravir for rescue or simplification of rescue therapy: 48 weeks' observational data. BMC Infect Dis. 2017 09 30; 17(1):658.
    View in: PubMed
    Score: 0.038
  6. Discontinuation of treatment and adverse events in an Italian cohort of patients on dolutegravir. AIDS. 2017 01 28; 31(3):455-457.
    View in: PubMed
    Score: 0.036
  7. Efficacy and tolerability of dolutegravir and two nucleos(t)ide reverse transcriptase inhibitors in HIV-1-positive, virologically suppressed patients. AIDS. 2017 01 28; 31(3):457-459.
    View in: PubMed
    Score: 0.036
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.